Christopher Van Tuyl

Executive

Directeur Juridique

Insider activity · 24 months0 buys7 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 1 saleJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 1 saleApr 26 · 0 buys · 1 saleMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 2 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 1 saleOct 26 · 0 buys · 1 sale

Total declarations

Company

▲ Purchases (0 ops.)

—

▼ Sales (9 ops.)

€537k

Latest filing published 09 Oct 2026 for Immunovant, Inc., €38k.

Filing timeline

BuySale

Christopher Van Tuyl

Insider track record

Disclosed buys

Disclosed sells

Signal history

Christopher Van Tuyl: trading record in brief

Christopher Van Tuyl is a declared insider of Immunovant, Inc. (senior executive), with filings sourced from SEC (Form 4). In total, 13 filings cover trades dated from 16 December 2024 to 7 October 2026.

Every open-market trade on record is a sale: 9 sales worth €537k. The totals exclude 2 filings filed without an amount. Outside the open market, there are 3 share grants and 1 option exercise. 2026 to date brings no purchases and 8 sales.

Most recently, on 9 October 2026, the filings show an open-market sale worth €38k in Immunovant, Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.